Carcinoma, Endometrioid  >>  pegylated liposomal doxorubicin  >>  Phase 1
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pegylated liposomal doxorubicin / Generic mfg.
NCT00003380: Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Terminated
1
US, Canada
etoposide, pegylated liposomal doxorubicin hydrochloride
Gynecologic Oncology Group, National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
07/02
 
NCT00006235: Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed
1
US
carboplatin, pegylated liposomal doxorubicin hydrochloride
Gynecologic Oncology Group, National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
02/06
 
NCT00003385: Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer

Completed
1
48
US, Europe
carboplatin, paclitaxel, pegylated liposomal doxorubicin hydrochloride
Gynecologic Oncology Group, National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
01/07
 
NCT01294293: TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Completed
1
20
US
TLR8 Agonist VTX-2337, Toll-like Receptor 8 Agonist VTX-2337, VTX-2337, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, pharmacological studies, Pegylated Liposomal Doxorubicin Hydrochloride, doxorubicin HCl liposome, TLC D-99, Paclitaxel, Anzatax, TAX
Gynecologic Oncology Group, National Cancer Institute (NCI)
Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Ovarian Carcinoma
07/14
 
NCT01489371: EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Completed
1
16
US
Laboratory Biomarker Analysis, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1, GEN-1, IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer, Nanoparticle-encased IL-12 DNA Plasmid Vector, phIL-12-005, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, DOX-SL, Doxil, Doxilen, Doxorubicin HCl Liposome, doxorubicin hydrochloride liposome, Duomeisu, Evacet, LipoDox, Liposomal Adriamycin, liposomal doxorubicin hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99
Gynecologic Oncology Group, National Cancer Institute (NCI)
Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
12/14
01/18

Download Options